Compare Sterling Biotech with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs PIRAMAL ENTERPRISES - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH PIRAMAL ENTERPRISES STERLING BIOTECH/
PIRAMAL ENTERPRISES
 
P/E (TTM) x -0.4 16.0 - View Chart
P/BV x 0.0 1.1 1.3% View Chart
Dividend Yield % 0.0 1.7 -  

Financials

 STERLING BIOTECH   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
PIRAMAL ENTERPRISES
Mar-19
STERLING BIOTECH/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs113,303 0.3%   
Low Rs31,797 0.2%   
Sales per share (Unadj.) Rs26.8716.5 3.7%  
Earnings per share (Unadj.) Rs-15.079.7 -18.8%  
Cash flow per share (Unadj.) Rs-5.5107.9 -5.1%  
Dividends per share (Unadj.) Rs028.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs54.91,477.5 3.7%  
Shares outstanding (eoy) m267.87184.45 145.2%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x0.33.6 7.3%   
Avg P/E ratio x-0.532.0 -1.5%  
P/CF ratio (eoy) x-1.323.6 -5.4%  
Price / Book Value ratio x0.11.7 7.3%  
Dividend payout %035.1 0.0%   
Avg Mkt Cap Rs m1,862470,292 0.4%   
No. of employees `0001.47.8 17.3%   
Total wages/salary Rs m54722,504 2.4%   
Avg. sales/employee Rs Th5,303.316,899.4 31.4%   
Avg. wages/employee Rs Th403.82,877.7 14.0%   
Avg. net profit/employee Rs Th-2,959.01,879.9 -157.4%   
INCOME DATA
Net Sales Rs m7,181132,153 5.4%  
Other income Rs m433,128 1.4%   
Total revenues Rs m7,223135,281 5.3%   
Gross profit Rs m94766,290 1.4%  
Depreciation Rs m2,5435,202 48.9%   
Interest Rs m4,37744,097 9.9%   
Profit before tax Rs m-5,93120,119 -29.5%   
Minority Interest Rs m03,194 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9248,611 -22.3%   
Profit after tax Rs m-4,00714,701 -27.3%  
Gross profit margin %13.250.2 26.3%  
Effective tax rate %32.442.8 75.8%   
Net profit margin %-55.811.1 -501.6%  
BALANCE SHEET DATA
Current assets Rs m14,335122,742 11.7%   
Current liabilities Rs m49,809310,810 16.0%   
Net working cap to sales %-494.0-142.3 347.1%  
Current ratio x0.30.4 72.9%  
Inventory Days Days40323 1,748.7%  
Debtors Days Days17139 439.4%  
Net fixed assets Rs m55,432116,904 47.4%   
Share capital Rs m268369 72.6%   
"Free" reserves Rs m13,935272,161 5.1%   
Net worth Rs m14,701272,530 5.4%   
Long term debt Rs m9,478270,196 3.5%   
Total assets Rs m73,988856,261 8.6%  
Interest coverage x-0.41.5 -24.4%   
Debt to equity ratio x0.61.0 65.0%  
Sales to assets ratio x0.10.2 62.9%   
Return on assets %0.56.9 7.3%  
Return on equity %-27.35.4 -505.2%  
Return on capital %-6.412.4 -51.7%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86015,200 12.2%   
Fx outflow Rs m254,889 0.5%   
Net fx Rs m1,83510,312 17.8%   
CASH FLOW
From Operations Rs m1,719-115,975 -1.5%  
From Investments Rs m-3,148-8,265 38.1%  
From Financial Activity Rs m1,426107,525 1.3%  
Net Cashflow Rs m-3-16,650 0.0%  

Share Holding

Indian Promoters % 33.9 52.9 64.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 4.0 -  
FIIs % 9.9 26.6 37.2%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 16.5 238.2%  
Shareholders   21,482 93,274 23.0%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  PANACEA BIOTECH  GLENMARK PHARMA  

Compare STERLING BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Inflation and Onion Effect: Your Inside Scoop on the Markets(Podcast)

Stock markets remained rangebound this week too. Macroeconomic news globally and domestically remained the focus of the week.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY19); Net Profit Up 21.8% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 21.8% YoY). Sales on the other hand came in at Rs 35 bn (up 22.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

What Is the IPO Euphoria Signaling Us About the Markets?(The 5 Minute Wrapup)

Dec 2, 2019

2019 will be remembered as the year of great money-making IPOs...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS